The Emerging Outcomes Demonstration / Cost Management Challenge
The current healthcare environment reshapes the three key factors in market access – value, evidence, and commercial positioning of [...]
Proposed change to CMS Rules Aim Will Expand Access to High-cost Therapies for Medicaid Recipients
The Medicaid Best Price rule requires drug manufacturers to give Medicaid the best price on all purchases. However, the rule [...]
What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence.
Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com, recently sat down with Dr. Anupam Jena, Scientific Advisor, Precision Xtract, to discuss his latest research that expands the definition and measurement of value of novel therapies by using new health economics evidence.
Real-world evidence and value-based contracting – swipe left or swipe right?
As biopharma makes the shift toward a personalized healthcare system, it is also transitioning towards a pipeline full of innovative, [...]
CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, [...]
Optimized Value Analytics – The Next Frontier for Payers and Pharma?
By Caitlin Rothermel, MA, MPHc Introduction If you’ve been following the health economics industry for the past few years, you’ve heard [...]
